Entamoeba histolytica develops resistance to complement deposition and lysis after acquisition of human complement regulatory proteins through trogocytosis

Hannah W. Miller¹, Tammie S.Y. Tam¹ and Katherine S. Ralston^{1*}

¹Department of Microbiology and Molecular Genetics, University of California, Davis, USA

* Address correspondence to Katherine S. Ralston, ksralston@ucdavis.edu

Running Title: Evasion of complement lysis by *Entamoeba histolytica*

ABSTRACT

Entamoeba histolytica is the cause of amoebiasis. The trophozoite (amoeba) form of this parasite is capable of invading the intestine, and can disseminate through the bloodstream to other organs. The mechanisms that allow amoebae to evade complement deposition during dissemination have not been well characterized. We previously discovered a novel complement-evasion mechanism employed by *E. histolytica*. *E. histolytica* ingests small bites of living human cells in a process termed trogocytosis. We demonstrated that amoebae were protected from lysis by human serum following trogocytosis of human cells, and that amoebae acquired and displayed human membrane proteins from the cells they ingested. Here, we aimed to define how amoebae are protected from complement lysis after performing trogocytosis. We found that amoebae were protected from complement lysis after ingestion of both human Jurkat T cells and red blood cells, and that the level of protection correlated with the amount of material ingested. Trogocytosis of human cells led to a reduction in deposition of C3b on the surface of amoebae. We asked whether display of human complement regulators is involved in amoebic protection, and found that CD59 was displayed by amoebae after trogocytosis. Deletion of a single complement regulatory protein, CD59 or CD46, from Jurkat cells was not sufficient to alter amoebic protection from lysis, suggesting that multiple, redundant complement regulators mediate amoebic protection. However, exogenous expression of CD46 or CD55 in amoebae was sufficient to confer protection from lysis. These studies shed light on a novel strategy for immune evasion by a pathogen.

21 **IMPORTANCE**

22 *Entamoeba histolytica* is the cause of amoebiasis, a diarrheal disease of global
 23 importance. While infection is often asymptomatic, the trophozoite (amoeba) form of this
 24 parasite is capable of invading and ulcerating the intestine, and can disseminate through the
 25 bloodstream to other organs. Understanding how *E. histolytica* evades the complement system
 26 during dissemination is of great interest. Here we demonstrate for the first time that amoebae
 27 that have performed trogocytosis (nibbling of human cells) resist deposition of the complement
 28 protein C3b. Amoebae that have performed trogocytosis display the complement regulatory
 29 protein CD59. Overall, our studies suggest that acquisition and display of multiple, redundant
 30 complement regulators is involved in amoebic protection from complement lysis. These
 31 findings shed light on a novel strategy for immune evasion by a pathogen. Since other parasites
 32 use trogocytosis for cell killing, our findings may apply to the pathogenesis of other infections.

INTRODUCTION

Amoebiasis remains a disease of global importance. The 2015 Global Burden of Disease Study estimated that it was responsible for 67,900 deaths worldwide that year (1). Its causative agent, *Entamoeba histolytica*, is prevalent in countries with poor sanitation and is spread through feces-contaminated food and water (2). In the rural area of Durango, Mexico, the seroprevalence of *E. histolytica* was found to be as high as 42% (3), and a longitudinal study of children living in an urban community of Dhaka, Bangladesh found that 80% were infected with the parasite by two years of age (4).

While infection with *E. histolytica* is often asymptomatic, it can result in diarrheal disease, colitis and extraintestinal abscesses (5). Following ingestion of the cyst form of the parasite, excystation occurs and the trophozoite stage (amoeba) colonizes the large intestine (6). Amoebae are capable of invading and ulcerating the intestine, causing tissue damage and bloody diarrhea. They can also disseminate through the bloodstream to other organs, most commonly the liver, where they form abscesses that are fatal if left untreated (5). The mechanisms that allow amoebae to evade complement deposition during dissemination have not been well characterized. Pathogenic strains of *E. histolytica* isolated from patients have been shown to be more resistant to complement lysis than nonpathogenic strains (7). It has also been found that the pathogenic amoeba species *E. histolytica* appears to be more resistant to complement than its nonpathogenic relative *E. dispar* (8). *E. histolytica* cysteine proteases can cleave complement components (9–11), and the Gal/GalNAc lectin has been described as a CD59 mimicry molecule (12). However, these mechanisms alone are not sufficient to fully

protect amoebae from complement lysis, as trophozoites are readily lysed by human serum *in vitro* (13).

We previously discovered a novel complement-evasion mechanism employed by *E. histolytica* (13). Trophocytosis, or “cell nibbling,” is present in many eukaryotes and occurs in a variety of contexts (14). In *E. histolytica*, trophocytosis is a process in which amoebae ingest small bites of living human cells (15). Our previous work has defined amoebic trophocytosis as both a mechanism for cell killing (15), and more recently, for immune evasion (13). We demonstrated that amoebae were protected from lysis by human serum following trophocytosis of human cells (13), and that amoebae acquired and displayed human membrane proteins from the cells they ingested (13). This work suggested a model in which amoebae incorporate proteins from human cells they eat on their surface, and these proteins in turn inhibit complement lysis.

In the present study, we aimed to define the mechanism by which amoebae are protected from complement lysis after performing trophocytosis. We found that trophocytosis of human cells reduced deposition of the complement protein C3b on the surface of amoebae, and that amoebae were protected from complement lysis after ingestion of both human Jurkat T cells and primary red blood cells. We identified the human complement regulatory protein CD59 (protectin) as one of the proteins that is taken from ingested human cells and displayed on the amoebic surface. Deletion of a single complement regulatory protein, CD59 or CD46, from human Jurkat cells was not sufficient to alter conferred protection on amoebae. However, exogenous expression of a single complement regulator, i.e., CD46 or CD55, in amoebae was sufficient to confer protection from lysis. Overall, these studies suggest that multiple, redundant complement regulators are involved in amoebic protection.

RESULTS

Ingestion of beads does not confer protection from complement lysis.

We previously showed that protection from complement lysis occurred in amoebae that had performed trogocytosis on living human cells, and that known inhibitors of trogocytosis also inhibited protection from complement lysis (13). Amoebae that had performed phagocytosis of dead human cells did not become protected from complement. Likewise, amoebae that were capable of trogocytosis, but defective in phagocytosis, nonetheless became protected from complement (13). To extend these findings, and to examine the role of ingestion on protection in the absence of host proteins, we allowed amoebae to ingest increasing concentrations of latex beads. Amoebae that ingested beads were no more protected from lysis than control amoebae that did not perform ingestion (**Fig. 1, S1**). Thus, trogocytosis confers protection from complement lysis, but phagocytosis of dead human cells or latex beads does not confer protection.

Amoebic protection from complement following trogocytosis is dose-dependent.

To determine if the amount of trogocytosed human cell material influenced protection, or if any level of trogocytosis was protective, we allowed amoebae to ingest incrementally larger amounts. Amoebae became increasingly protected from complement lysis (**Fig. 2b-c, S2a**) after ingesting higher quantities of live Jurkat cell material (**Fig. 2a, 2g**). Thus, acquired protection from complement lysis correlates with the amount of human cell material ingested through trogocytosis.

We next asked if protection could be conferred through trogocytosis of primary human cells. During invasive infections, amoebae breach the intestinal wall and disseminate via the

bloodstream. Detection of amoebae containing ingested red blood cells in the stool has previously been used as a diagnostic for invasive disease (16). Therefore, we asked if ingestion of human red blood cells would lead to protection. Amoebae were allowed to ingest increasing numbers of human red blood cells. Increased trogocytosis of red blood cells led to increased protection from complement lysis (**Fig. 2d-f, 2h, S2b**). These results support a model where the level of protection from complement lysis is proportional to the amount of human cell material that was ingested during trogocytosis.

Amoebic trogocytosis of human cells inhibits deposition of complement C3b.

It can be inferred that lysis of amoebae by human serum is due to complement activity because heat-inactivated serum does not lyse amoebae (13). Here, we formally tested if trogocytosis of human cells led to reduced deposition of complement on the amoebae surface. Amoebae that had been co-incubated with live human cells had less death and less deposited human C3b on their surface than amoebae that were incubated in the absence of Jurkat cells (**Fig. 3a-b, S3**). Furthermore, live amoebae had less deposited C3b than dead amoebae (**Fig. 3c, 3e**). Amoebae that had been co-incubated with human cells had less deposited C3b, compared to amoebae that were incubated in the absence of Jurkat cells (**Fig. 3d**). Therefore, trogocytosis of human cells prevents complement lysis of amoebae and inhibits deposition of complement C3b.

Amoebae acquire the complement regulatory proteins CD59 and CD46 from human cells.

We hypothesized that protection from complement lysis was due to display of human complement regulatory proteins. We first chose to look at acquisition of the complement regulatory protein CD59 (protectin), a membrane protein that is expressed by both Jurkat cells

and human red blood cells (17–19). CD59 inhibits terminal components of the complement cascade and formation of the membrane attack complex (17, 20–22). After amoebae had performed trogocytosis, patches of CD59 were detected on the amoeba surface within five minutes (**Fig. 4a**) and a larger quantity of CD59 patches were detected on the amoeba surface after one hour of trogocytosis (**Fig. 4a-c**). The patchy/punctate localization pattern was similar to the localization pattern of other human proteins displayed by amoebae after trogocytosis (13). Importantly, the apparent display of human membrane proteins by amoebae was not an artifact of paraformaldehyde fixation, since the appearance of human membrane proteins displayed by amoebae was indistinguishable, whether staining was performed before or after fixation (**Fig. S4** and (13)). Since the heavy chain of the amoeba surface Gal/GalNAc lectin has been implicated as a CD59 mimicry molecule (12, 23), we asked if the CD59 antibody used in these assays cross-reacted with the Gal/GalNAc lectin. CD59 was not detected on control amoebae that had not performed trogocytosis (**Fig. 4a**), showing that the CD59 antibody did not cross-react with the Gal/GalNAc lectin.

Imaging flow cytometry analysis was used to quantify amoebic acquisition of CD59. Human cell nuclei are not ingested during trogocytosis (15). Therefore, labeling of human cell nuclei was used to differentiate intact, extracellular human cells from patches of human proteins displayed on amoebae. Patches of displayed human CD59 were detected on amoebae that had performed trogocytosis, but not on amoebae that were incubated in the absence of Jurkat cells (**Fig. 5a-c, S5**). Amoebae had ~38% more displayed CD59 after one hour of trogocytosis than after five minutes (**Fig. 5b**). These findings indicate that amoebae acquired

and displayed CD59 within five minutes of trogocytosis, and the quantity of displayed CD59 increased over time.

To determine if more than one complement regulatory protein was displayed by amoebae after trogocytosis, immunofluorescence was used to detect human CD46. CD46 (membrane cofactor protein) is expressed by human Jurkat cells (24) and acts as a co-factor for serum factor I, which cleaves and inactivates complement components C3b and C4b (25–27). After amoebae had performed trogocytosis, patches of CD46 were detected on the amoeba surface within five minutes (**Fig. S6**). Thus, amoebae acquire and display multiple complement regulatory proteins, after performing trogocytosis of human cells.

Removal of GPI-anchored surface proteins trends towards restoring complement lysis of amoebae.

We next sought to test the effect of removing complement regulatory proteins on conferred protection. CD59 is a glycosylphosphatidylinositol (GPI) anchored protein that can be cleaved with the enzyme phosphatidylinositol-specific phospholipase C (PI-PLC) (17, 18, 20, 22). In addition to removing CD59, treatment with PI-PLC also cleaves the GPI-anchored complement regulatory protein CD55 (decay-accelerating factor) (28, 29). CD55 is expressed by both Jurkat cells and human red blood cells (19, 30) and accelerates the decay of C3 and C5 convertases of the classical and alternative complement pathways (30, 31). Amoebae were allowed to perform trogocytosis or incubated in the absence of Jurkat cells, and then treated with PI-PLC before exposure to human serum. Heat-inactivated PI-PLC was used as a control. PI-PLC treatment appeared to reduce amoebic protection from complement lysis (**Fig. S7, S8a**). However, this difference was not statistically significant. This is likely to be due to the higher

levels of variability in this assay, which were due to the prolonged incubation of amoebae on ice during PI-PLC treatment. Indeed, due to the incubation on ice, the background level of amoeba cell death was much higher than usual. These findings suggested that removal of all GPI-anchored proteins reduces amoebic protection from complement lysis, but did not prove a causal relationship.

Removal of CD59 and CD46 is not sufficient to sensitize amoebae to complement lysis.

Due to the higher levels of variability that we observed with PI-PLC treatment, we next used human cell mutants to test whether individual proteins were required for protection from complement lysis. We tested the requirements for CD59 and CD46. In order to determine if acquisition and display of human CD59 or CD46 molecules was required for protection from complement, we used CRISPR/Cas9 to create human cell knockout mutants that lacked these proteins. Sanger sequencing (**Fig. S9**) and antibody staining of CD59 (**Fig. 6a-b**) and CD46 (**Fig. 6c-d**) showed that knockout mutants were successfully generated. Amoebae that were allowed to perform trophocytosis on control human cells or cells that lacked either CD59 or CD46 were equally protected from complement lysis (**Fig. 6e, S8**). Additionally, there was no difference in the amount of ingested human cell material (**Fig. 6f**). These findings reveal that removal of either CD59 or CD46 individually is not sufficient to sensitize amoebae to complement lysis. Furthermore, they hint at redundancy in the mechanism of protection and that amoebae likely acquire and display multiple complement regulatory proteins from the cells they ingest.

Display of CD46 or CD55 is sufficient to protect amoebae from complement lysis.

To ask if display of human complement regulatory proteins was sufficient to protect amoebae from lysis, we created amoebae that exogenously expressed either human CD46 or

CD55 (**Fig. 7, S2a**). Expression of CD46 or CD55 was detectable with RT-PCR analysis (**Fig. 7a**). Immunofluorescence analysis showed that CD46 or CD55 proteins were surface-localized in amoebae, as they were detected with antibody staining of non-permeabilized cells (**Fig. 7b-j, S2a**). Localization of the *E. histolytica* surface Gal/GalNAc lectin was used as a control (**Fig. 7d, 7g, 7j**), and all transfected amoebae had equivalent amounts of Gal/GalNAc lectin. CD46 or CD55 expression was at a relatively low level (**Fig. 7b-c, 7e-f**), just above background fluorescence of vector control amoebae. Additionally, CD46 or CD55 expression was markedly lower than the expression level of the Gal/GalNAc lectin (**Fig. 7d, 7g**). When exposed to human serum, amoebae that expressed human CD46 or CD55 were more protected from lysis than vector control amoebae (**Fig. 8, S8b**). Therefore, display of a single complement regulatory protein is sufficient to protect amoebae from complement lysis.

DISCUSSION

Our findings reveal that amoebae are protected from complement lysis through trogocytosis of human cells and that trogocytosis leads to less deposited C3b on the amoeba surface. Amoebae acquire protection from both human Jurkat cells as well as primary red blood cells and conferred protection is proportional to the amount of ingested human cell material. Trogocytosis of human cells results in the display of the complement regulatory protein CD59 on the amoebae surface. Finally, although removal of the individual complement regulatory proteins, CD59 or CD46 was not sufficient to sensitize amoebae to complement lysis, the display of an individual complement regulatory protein, CD46 or CD55, was sufficient to protect amoebae from complement lysis.

Many studies have shown that cancer cells overexpress complement regulatory molecules, allowing them to evade complement lysis. However, it should be noted that expression levels vary widely between cell types and between individual studies (32). Removal of GPI-anchored proteins, which include the complement regulatory proteins CD59 and CD55 but not CD46, with PI-PLC treatment resulted in enhanced susceptibility of cancer cells to complement lysis (28, 29). This is consistent with our finding that PI-PLC treated amoebae that had undergone trogocytosis of human cells, and been made resistant to complement, became more sensitive to complement lysis. Treatment with PI-PLC removes other GPI-anchored proteins in addition to CD59 and CD55, so we cannot rule out the possibility that loss of other membrane proteins contributed to the loss of complement resistance in our PI-PLC treated amoebae.

Amoebae that were engineered to express complement regulatory proteins became protected from lysis by human complement. We were unable to express human CD59 in amoebae, as although stably transfected amoebae with a CD59 expression construct were successfully recovered, these transfectants grew slowly and could not be maintained over time. While CD59 expression was detectable by RT-PCR, it is possible that the CD59 protein mis-localized in amoebae, or otherwise led to deleterious effects. CD46 and CD55 were each appropriately localized to the amoeba cell surface, as evidenced by immunofluorescence staining, and by the functional protection from complement lysis that they conferred. Notably, CD46 and CD55 were not greatly overexpressed in amoebae. When using immunofluorescence, CD46 and CD55 staining levels were just above the background levels of fluorescence seen in vector control amoebae. Thus, these proteins led to protection from complement lysis without dramatically high levels of expression. Only a single complement regulator at a low expression level was needed for protection from lysis by complement. These findings fit with the generally relatively low endogenous expression levels of complement regulatory proteins in human cells, in that low levels of these proteins are sufficient to inhibit the complement pathway.

There have been several studies that examined the efficacy of using blocking antibodies against complement regulatory proteins to enhance lysis of cancer cells. Results from blocking individual proteins have been highly variable in different cell types but blocking one or more proteins was effective in many cases. Using antibodies against CD46 was rarely effective, however antibodies against CD59 and CD55 often were effective in enhancing complement lysis (32). Additionally, there appears to be an additive effect when multiple proteins are targeted at once. Cervical carcinoma cells were rendered more susceptible to complement after treatment

with blocking antibodies to CD59 and CD55, and lysis was increased further when cells were treated with both antibodies (33). Similarly, breast carcinoma cells, were more easily lysed after treatment with anti-CD59 and anti-CD55 antibodies, but a much higher degree of lysis was achieved when a mixture of anti-CD59, anti-CD55, and anti-CD46 antibodies was used (34). Since neither removal of CD46 or CD59 was sufficient to sensitize amoebae to complement lysis, it is possible that amoebic display of multiple different complement regulators enables protection from lysis. In our assays, we used a 1:40 ratio of amoebae to Jurkat cells, a ratio that led to a high level of protection from complement lysis. It is possible that using fewer human cells, to lead to a suboptimal level of protection from complement lysis, might have more sensitively revealed differences in amoebic protection from complement lysis due to subtle perturbations like the loss of individual human complement regulators. While removal of CD46 or CD59 did not sensitize amoebae to complement lysis, these proteins could still contribute to amoebic complement protection, as part of a collection of multiple redundant, complement regulators that protect amoebae from lysis. Indeed, experiments in which amoebae were engineered to express complement regulators showed that display of CD46 or CD55 was sufficient to protect amoebae from lysis, supporting the relevance of these proteins in protecting amoebae that have performed trogocytosis.

Our results support a model whereby amoebae are protected from serum lysis in the blood through trogocytosis of red blood cells they encounter there, and potentially from other cells they encounter before reaching the bloodstream. Amoebae likely acquire and display multiple complement regulatory proteins from the human cells that they ingest, which then leads to less C3b deposition, and protection from complement lysis.

MATERIALS AND METHODS

Cell culture

E. histolytica trophozoites (HM1:IMSS) from ATCC (amoebae) were cultured as described previously (13, 35). Amoebae were maintained in glass tissue culture tubes at 35°C in TYI-S-33 medium supplemented with 15% heat-inactivated adult bovine serum (Gemini Bio-Products), 2.3% Diamond vitamin Tween 80 solution (40×; Sigma-Aldrich), and 80 U/ml penicillin, 80 µg/ml streptomycin (Gibco). Amoebae were expanded in T25 un-vented tissue culture flasks and harvested when flasks reached 80% confluence. When used in serum lysis or immunofluorescence assays, amoebae were resuspended in M199s medium (Gibco medium M199 with Earle's salts, L-glutamine, and 2.2 g/liter sodium bicarbonate, without phenol red) supplemented with 0.5% bovine serum albumin (BSA), 25 mM HEPES, and 5.7 mM L-cysteine.

Human Jurkat T cells (clone E6-1) from ATCC were grown in vented T25 tissue culture flasks at 37°C and 5% CO₂ as previously described (13). Jurkat cells were cultured in RPMI 1640 medium (Gibco; RPMI 1640 with L-glutamine and without phenol red) supplemented with 10% heat-inactivated fetal bovine serum (Gibco), 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 mM HEPES. Jurkat cells were expanded in T75 vented tissue culture flasks and harvested when cell density reached between 5×10^5 and 2×10^6 cells/ml. Jurkat cells were resuspended in M199s medium for use in serum lysis or immunofluorescence assays.

Single donor human red blood cells separated from whole blood by centrifugation and negative for the presence of human immunodeficiency virus-1 (HIV-1), HIV-2, HIV-1 antigen or HIV-1 nucleic acid test, hepatitis B surface antigen, hepatitis C virus, syphilis, and alanine aminotransferase test were purchased from Innovative Research (Cat# IWB3CPDA1UNIT). Red

blood cells were stored at 4°C and resuspended in M199s medium prior to use in serum lysis assays.

DNA constructs

For creation of Jurkat cell CRISPR knockout mutants, guide RNAs (gRNA) to human CD59 or CD46 were cloned into a pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid backbone (pX330-U6-Chimeric_BB-CBh-hSpCas9 was a gift from Feng Zhang (Addgene plasmid # 42230; <http://n2t.net/addgene:42230> ; RRID:Addgene_42230) (36)). Guide RNAs were created by using the sequences designed by Thielen et. al, 2018 (37). The gRNA oligos used are presented in Table 1 with BbsI restriction enzyme overhangs shown in bold. Guide RNAs were cloned into the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid backbone using a modified version of the Zhang Lab General Cloning Protocol (Addgene <http://www.addgene.org/crispr/zhang/>). Briefly, the px330 plasmid backbone was digested with BbsI restriction enzyme (FastDigest Bpil: ThermoFisher Scientific). Guide RNA oligos containing BbsI overhangs were then phosphorylated and annealed. Next, annealed oligos were ligated into the pX330 plasmid backbone and NEB 5-alpha Competent *E. coli* were transformed (New England Biolabs). Positive colonies were screened by restriction digest. Plasmids with the correct inserts were confirmed by Sanger sequencing using the “U6” Universal Primer from GENEWIZ (LKO.1 5’) which is located in the human U6 promoter (**Table 1**).

To generate amoebic expression constructs for exogeneous expression of human proteins, the coding regions of human CD46 or CD55 were amplified from human Jurkat cells. Briefly, RNA was extract from Jurat cells using the Direct-zol RNA MiniPrep Plus kit (Zymo Research) and cDNA was prepared. Next, the coding sequences for human CD46 or CD55 were

amplified from Jurkat cDNA by PCR using primers described in **Table 1**. The amplified CD46 or CD55 inserts were then cloned into the *E. histolytica* expression plasmid pEhEx backbone (38) using the Gibson Assembly Ultra Kit (VWR). Primers used for Gibson cloning are described in **Table 1**. For creation of the CD46 expression plasmid, both the pEhEx backbone and the CD46 insert were PCR amplified with primers that added 20 base pairs corresponding to the ends of the insert or backbone, respectively. For creation of the CD55 expression plasmid, the pEhEx backbone was digested using XhoI (New England Biolabs) and the CD55 insert was PCR amplified with primers that added 20 base pairs corresponding to the ends of the backbone. NEB 5-alpha Competent *E. coli* were transformed, and positive colonies were screened by restriction digest analysis. Sanger sequencing was used to assess the sequences of the inserts and flanking vector sequences, using primers located in the Cysteine synthase A gene [EHI_024230] 5' and 3' UTR regions (**Table 1**). The CD46 gene insert corresponds to the mRNA transcript variant d (GenBank accession number: NM_153826) and the CD55 gene insert corresponds to mRNA transcript variant 1 (GenBank accession number: NM_000574).

Jurkat T cell CRISPR/Cas9 mutants

Human Jurkat T cells were transfected with pX330 plasmids containing the CD59 gRNA, the CD46 gRNA, or the pX330 backbone as a control. Plasmid DNA was isolated in an endotoxin-free manner (GenElute™ HP Endotoxin-Free Plasmid Maxiprep Kit; Sigma-Aldrich) and concentrated using paramagnetic beads (HighPrep PCR Clean Up System; Magbio). Jurkat T cells were transfected using the Neon Transfection System (Invitrogen) with the 10 µl tip and 24 well plate format. Cells were prepared, and the Neon Transfection System was used according to

the manufacturer's instructions. The transfection conditions used were as follows: volts = 1050, width = 30 and pulse # = 2.

When creating the CD59 and CD46 knockout mutants, 1.8 µg of plasmid DNA was used with 1×10^5 cells per transfection reaction and two reactions were performed for each plasmid and transferred to 1 well of a 24 well plate. Transfection efficiency was calculated by separately transfecting an enhanced green fluorescent protein (EGFP) expression plasmid pcDNA3-EGFP (pcDNA3-EGFP was a gift from Doug Golenbock (Addgene plasmid # 13031 ; <http://n2t.net/addgene:13031> ; RRID:Addgene_13031)) in parallel. Percentage of EGFP expressing cells was calculated after 24 hours by fixing samples with 4% paraformaldehyde (Electron Microscopy Sciences) and analyzing with imaging flow cytometry. To generate CD59 expressing Jurkat cells, 2 µg of plasmid DNA was used with 2×10^5 cells per transfection reaction and two reactions were performed for each plasmid and transferred to 1 well of a 24 well plate.

Clonal lines of Jurkat cell mutants were obtained by limiting dilution in 96 well plates. Clonal lines were screened for knockout by labeling with primary mouse monoclonal antibodies to CD59 (clone MEM-43/5; Abcam) or CD46 (clone C-10; Santa Cruz Biotechnology) and a Cy^{TM}5 AffiniPure Goat Anti-Mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc). Samples were analyzed by imaging flow cytometry. Knockout was confirmed in positive clones by isolating genomic DNA using the Quick-DNA Miniprep kit (Zymo Research) and polymerase chain reaction (PCR) amplifying regions of either CD59 or CD46. Primer sets had been identified in BLAST as specific to these genes (**Table 1**). Next, purified PCR product was sequenced with primers upstream of the predicted CRISPR/Cas9 cut site (**Table 1**) and knockout was confirmed.

Characterization of amoebae exogenously expressing human CD46 or CD55

Amoebae were transfected as described previously (13). Briefly, amoebae were transfected with 20 µg of the human CD46 or CD55 expression construct, or the pEhEx plasmid backbone using Attractene transfection reagent (Qiagen). Stable transfectants were initially selected at 3 µg/ml Geneticin (ThermoFisher Scientific), and then maintained at 6 µg/ml Geneticin. Before use in immunofluorescence assays and serum lysis experiments, drug selection was gradually increased from 6 µg/ml to 48 µg/ml Geneticin, to increase plasmid copy number. Amoebae were maintained at 48 µg/ml Geneticin for 24 hours before experiments were performed.

Expression of human CD46 and CD55 was confirmed using RT-PCR analysis of amoebae maintained at 3 µg/ml Geneticin. RNA was extracted using the Direct-zol RNA MiniPrep Plus kit (Zymo Research) and cDNA was made. Primers used for RT-PCR are shown in Table 1. RT-PCR was performed as described (35).

Imaging flow cytometry

To detect human CD59 displayed on amoebae following trogocytosis, Jurkat cells were with labeled Hoechst 33342 dye (Invitrogen) at 5 µg/ml for 30 minutes at 37°C. Amoebae were washed and resuspended in M199s medium and labeled with CellTracker green 5-chloromethylfluorescein diacetate (CMFDA; Invitrogen) at 186 ng/ml for 10 minutes at 35°C. Amoebae and Jurkat cells were then washed and resuspended in M199s medium. Amoebae were resuspended at 4×10^5 cells/ml and Jurkat cells were resuspended at 1.6×10^7 cells/ml for a 1:40 amoeba: Jurkat cell ratio. Amoebae and Jurkat cells were co-incubated for either 5 minutes or 1 hour, or amoebae were incubated in the absence of Jurkat cells. Cells were fixed with 4% PFA for 30 minutes at room temperature. Samples were blocked in 1 x PBS containing

0.1% Tween20 (Sigma-Aldrich) (1 x PBST), 5% BSA and 20% Normal Goat Serum (Jackson ImmunoResearch Laboratories, Inc) for 1 hour at room temperature on a rocker. Next, samples were labeled with primary mouse monoclonal antibodies to CD59 (clone MEM-43/5; Abcam) diluted 1:50 in blocking solution at 4°C overnight on a rocker. Samples were washed with 1 x PBST and labeled with a Cy5 AffiniPure Goat Anti-Mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc) stored in 50% glycerol (Sigma-Aldrich). The secondary antibody was diluted 1:100 in blocking solution, for a final dilution of 1:200, and incubated for 3 hours at room temperature on a rocker. Lastly, samples were washed with 1 x PBST, resuspended in 50 µl 1 x PBS, and run on an Amnis ImageStreamX Mark II. 10,000 events were collected for conditions where amoebae were incubated in the absence of Jurkat cells and 100,000 events were collected for conditions where amoebae were incubated with Jurkat cells. Data are from 5 replicates across 3 independent experiments. The no primary control condition was performed in 2 of 3 independent experiments and data are from 3 replicates. See Figure S5 for the analysis gating scheme.

To detect human CD46 displayed on amoebae following trogocytosis, amoebae and Jurkat cells were labeled in the same manner as for detection of CD59. Amoebae and Jurkat cells were co-incubated for 5 minutes or amoebae were incubated in the absence of Jurkat cells. Samples were labeled with a primary mouse monoclonal antibody to human CD46 (Clone C-10; Santa Cruz Biotechnology) at a 1:10 dilution, followed by a Cy5 AffiniPure Goat Anti-Mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc). Amoebae were gated on by size and 10,000 events were collected per sample. Data are from 2 replicates and 1 independent experiment.

For detection of CD46, CD55, or Gal/GalNAc lectin expression on amoebae exogenously expressing CD46 or CD55, amoebae were labeled with CMFDA and prepared in the same manner as for detection of displayed human CD59. Following fixation, samples were blocked overnight at 4°C on a rocker. Samples were then labeled with primary mouse monoclonal antibodies to human CD46 (Clone C-10; Santa Cruz Biotechnology) human CD55 (Clone NaM16-4D3; Santa Cruz Biotechnology) or the *E. histolytica* Gal/GalNAc lectin (Clone 7F4; the Gal/GalNAc lectin antibody was a gift from William A. Petri, Jr., University of Virginia (39)) overnight at 4°C on a rocker. The CD46 and CD55 primary antibodies were diluted 1:10 and the Gal/GalNAc lectin primary antibody was diluted 1:50 in blocking solution. Samples were labeled with secondary antibody as described above. Amoebae were gated on by size and 10,000 events were collected per sample. Data are from 3-4 replicates from 2 independent experiments. See Figure S2a for the analysis gating scheme.

Confocal microscopy

To detect displayed CD59 on the amoeba surface after trophocytosis, cells were labeled for confocal microscopy as described previously (13). Amoebae were prepared in the same manner as the for the detection of displayed CD59 using imaging flow cytometry (above) with an approximate fourfold increased concentration of CMFDA. After labeling with antibodies, samples were mounted using Vectashield (Vector Laboratories) on Superfrost Plus microslides (VWR) with glass coverslips. Slides were imaged on an Intelligent Imaging Innovations hybrid Spinning Disk Confocal-TIRF-Widefield Microscope. 136 Images were collected from 1 independent experiment. FIJI software was used for image analysis (40).

For detection of displayed biotinylated human cell membrane proteins, amoebae were left unstained in some experiments or labeled with CMFDA as described above. Human Jurkat cells were biotinylated as described previously (13). Briefly, Jurkat cells were biotinylated with EZ-Link Sulfo-NHS-SS-Biotin (ThermoFisher Scientific) at 480 µg/ml in 1× PBS for 25 min at 4°C. The reaction was quenched using 100 mM Tris-HCl (pH 8) and washed with washed in 100 mM Tris-HCl (pH 8) before being resuspending M199s medium. Amoebae were incubated with biotinylated Jurkat cells at a 1:5 ratio for 2 - 5 minutes and then immediately placed on ice. Next, samples were stained with Alexa Fluor 633 conjugated streptavidin (Invitrogen) at 20 µg/ml for 1 hour at 4°C, prior to fixation with 4% paraformaldehyde for 30 minutes at room temperature. In some experiments, samples were labeled with DAPI (4',6-diamidino-2-phenylindole; Sigma-Aldrich) for 10 minutes at room temperature following fixation. Samples were mounted on either poly-lysine (Sigma-Aldrich) or collagen (collagen I, rat tail; Gibco) coated coverslips for 1 hour. Samples were mounted with Vectashield on glass slides, and slides were imaged on an Olympus FV1000 laser point-scanning confocal microscope.

Serum lysis assays

For experiments where amoebae were incubated with increasing numbers of Jurkat cells, amoebae were washed and resuspended in M199s medium and labeled with CMFDA at 186 ng/ml for 10 minutes at 35°C. Jurkat cells were washed and labeled in M199s with DiD at 21 µg/ml for 5 minutes at 37°C and 10 minutes at 4°C. Amoebae were washed and resuspended at 4 x 10⁵ cells/ml. Jurkat cells were washed a resuspended at 2 x 10⁶ cells/ml, 4 x 10⁶ cells/ml, 8 x 10⁶ cells/ml and 1.6 x 10⁷ cells/ml. Amoebae were incubated in the absence of Jurkat cells or the presence of Jurkat cells at a 1:5, 1:10, 1:20, and 1:40 ratio for 1 hour at 35°C.

Next, samples were resuspended in 100% normal human serum (pooled normal human complement serum; Innovative Research Inc.) supplemented with 150 μ M CaCl₂ and 150 μ M MgCl₂ for 30 minutes at 35°C as described previously (13). Following exposure to human serum, samples were resuspended in M199s medium and labeled using Zombie Violet Fixable Viability dye (BioLegend), prepared according to the manufacturer's instructions, at a concentration of 4 μ l/ml for 30 minutes on ice. Next, samples were fixed with 4% PFA at room temperature for 30 minutes. Samples were then resuspended in 50 μ l 1 x PBS, and run on an Amnis ImageStreamX Mark II. 10,000 events were collected for samples where amoebae were incubated in the absence of Jurkat cells or with Jurkat cells at a 1:5 ratio. 10,00 – 20,000 events were collected for samples with Jurkat cells at a 1:10 ratio, 10,00 - 40,000 events were collected for samples with a 1:20 ratio, and 50,000 - 80,000 events for samples with a 1:40 ratio. Data are from 6 replicates across 3 independent experiments. See Figure S2 for the analysis gating scheme.

For experiments with CD59 and CD46 knockout mutants, the serum lysis assay used was the same as described above, except only a 1:40 ratio of amoebae to Jurkat cells was used, instead of multiple different ratios. Amoebae were incubated in the absence of Jurkat cells, in the presence of Jurkat cells transfected with the px330 vector control, or with either CD59 or CD46 knockout Jurkat cell mutants at a 1:40 ratio. Cells were gated on by size and 10,000 events from the amoebae that were incubated in the absence of Jurkat cells and 100,000 events from the amoebae incubated with Jurkat cells were collected. Data are from 6 replicates across 3 independent experiments. See Figure S8a for the analysis gating scheme.

In experiments where samples were treated with phospholipase C, the assay was performed as described above with the addition of a treatment step preceding exposure to serum. Only a 1:40 ratio of amoebae to Jurkat cells was used, instead of multiple different ratios. Following coincubation of amoebae and Jurkat cells, samples were immediately placed on ice and resuspended in ice-cold M199s medium. Samples were treated with either 500 mU of Phospholipase C (PI-PLC) (Phospholipase C, Phosphatidylinositol-specific from *Bacillus cereus*; Sigma-Aldrich) prepared according to the manufacturer's instructions, or 500 mU heat-inactivated PI-PLC. PI-PLC was heat-inactivated at 95°C for 30 minutes. PI-PLC was carried out on ice, on a rocker, in a 4°C cold room for 30 minutes. Cells were gated on by size and 10,000 events from the amoebae incubated in the absence of Jurkat cells and 100,000 events from the amoebae incubated with Jurkat cells were collected. Data are from 8 replicates across 4 independent experiments. The untreated control condition was performed 3 of 4 independent experiments and data are from 6 replicates. See Figure S8a for the analysis gating scheme.

For experiments where amoebae were incubated with increasing numbers of red blood cells, amoebae were incubated with red blood cells resuspended at 4×10^6 cells/ml, 4×10^7 cells/ml, and 4×10^8 cells/ml for a 1:10, 1:100, and 1:1000 amoebae to red blood cell ratio. The amoeba population was gated on by size and 10,000 amoeba events were collected for samples where amoebae were incubated in the absence of red blood cells or with red blood cells at a 1:10 ratio, a 1:100 ratio. 100,000 events were collected for amoebae incubated with red blood cells at a 1:1000 ratio. Data are from 6 replicates from 3 independent experiments. See Figure S2b for the analysis gating scheme.

For C3b experiments, amoebae were labeled with CMFDA and Jurkat cells were left unlabeled. Amoebae and Jurkats were incubated together at a 1:40 amoebae: Jurkat ratio. After fixation, samples were blocked in 1 x PBST containing 5% BSA and 20% Normal Goat Serum for 30 minutes at room temperature on a rocker. Samples were then labeled with a mouse monoclonal antibody to complement components C3b and iC3b (Clone 3E7; Sigma-Aldrich) diluted 1:100 in blocking solution at 4°C overnight on a rocker. Samples were washed in 1 x PBST and labeled with an Alexa Fluor 47 AffiniPure Fab Fragment Donkey Anti-Mouse secondary antibody (Jackson ImmunoResearch Laboratories, Inc) stored in 50% glycerol (Sigma-Aldrich). The secondary antibody was diluted 1:100 in blocking solution for a final dilution of 1:200, and samples were incubated for 3 hours at room temperature on a rocker. Samples were washed in 1 x PBST, resuspended in 50 µl 1 x PBS, and run on an Amnis ImageStreamX Mark II. 10,000 events were collected in samples where amoebae were incubated in the absence of Jurkat cells and 100,000 events were collected in samples where amoebae were incubated with Jurkat cells. Data are from 6 replicates across 3 independent experiments. See Figure S3 for the analysis gating scheme.

For latex bead ingestion experiments, amoebae were left unstained and incubated with either 3×10^6 or 1.5×10^7 fluorescent red carboxylate-modified polystyrene 2.0 µm latex beads (Sigma-Aldrich) or incubated in the absence of latex beads. Amoebae were gated on by size and 10,000 events were collected per sample. Data are from 4 replicates across 2 independent experiments. See Figure S1 for the gating scheme used for analysis.

For experiments with amoebae exogenously expressing human CD46 or CD55, amoebae or vector control amoebae were labeled with CMFDA. Amoebae were either treated with

M199s medium or exposed to human serum as described above. After gating on amoebae by size, 10,000 events were collected per sample. Data are from 8 replicates across 4 independent experiments. See Figure S8b for the gating scheme used for analysis.

Statistical analysis

GraphPad Prism software was used to perform all statistical analyses and the means and standard deviation values are displayed on all data plots. Analyses were done using a Student's unpaired t test (no significant difference was indicated by a P of >0.05; *, $P \leq 0.05$; **, $P \leq 0.01$; ***, $P \leq 0.001$; ****, $P \leq 0.0001$).

507   **ACKNOWLEDGMENTS**

508   We thank Dr. Scott Dawson, Dr. Stephen McSorley, and the members of our laboratory
509   for helpful discussions. All ImageStream and confocal data were acquired using shared
510   instrumentation in the UC Davis MCB Light Microscopy Imaging Facility. We thank Dr. Michael
511   Paddy for technical support in the use of these instruments. T.S.Y.T. was funded by the Khaira
512   Family Experiential Learning Award through the UC Davis College of Biological Sciences. This
513   work was funded by NIH grant AI146914 and a Pew Scholarship awarded to K.S.R.

514 **AUTHOR CONTRIBUTIONS**

515   H.W.M. designed, performed, and analyzed the experiments. T.S.Y.T. created and
 516 characterized amoebae exogenously expressing complement regulatory proteins. K.S.R.
 517 conceived of the overall approach and oversaw the design and analysis of the experiments.
 518 H.W.M. and K.S.R. wrote the manuscript.

REFERENCES

1. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, Casey DC, Charlson FJ, Chen AZ, Coates MM, Coggeshall M, Dandona L, Dicker DJ, Erskine HE, Ferrari AJ, Fitzmaurice C, Foreman K, Forouzanfar MH, Fraser MS, Fullman N, Gething PW, Goldberg EM, Graetz N, Haagsma JA, Hay SI, Huynh C, Johnson CO, Kassebaum NJ, Kinfu Y, Kulikoff XR, Kutz M, Kyu HH, Larson HJ, Leung J, Liang X, Lim SS, Lind M, Lozano R, Marquez N, Mensah GA, Mikesell J, Mokdad AH, Mooney MD, Nguyen G, Nsoesie E, Pigott DM, Pinho C, Roth GA, Salomon JA, Sandar L, Silpakit N, Sligar A, Sorensen RJD, Stanaway J, Steiner C, Teeple S, Thomas BA, Troeger C, VanderZanden A, Vollset SE, Wanga V, Whiteford HA, Wolock T, Zoeckler L, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abera SF, Abreu DMX, Abu-Raddad LJ, Abyu GY, Achoki T, Adelekan AL, Ademi Z, Adou AK, Adsuar JC, Afanvi KA, Afshin A, Agardh EE, Agarwal A, Agrawal A, Kiadaliri AA, Ajala ON, Akanda AS, Akinyemi RO, Akinyemiju TF, Akseer N, Lami FHA, Alabed S, Al-Aly Z, Alam K, Alam NKM, Alasfoor D, Aldhahri SF, Aldridge RW, Alegretti MA, Aleman AV, Alemu ZA, Alexander LT, Alhabib S, Ali R, Alkerwi A, Alla F, Allebeck P, Al-Raddadi R, Alsharif U, Altirkawi KA, Martin EA, Alvis-Guzman N, Amare AT, Amegah AK, Ameh EA, Amini H, Ammar W, Amrock SM, Andersen HH, Anderson BO, Anderson GM, Antonio CAT, Aregay AF, Ärnlov J, Arsenijevic VSA, Artaman A, Asayesh H, Asghar RJ, Atique S, Avokpaho EFGA, Awasthi A, Azzopardi P, Bacha U, Badawi A, Bahit MC, Balakrishnan K, Banerjee A, Barac A, Barker-Collo SL, Bärnighausen T, Barregard L, Barrero LH, Basu A, Basu S, Bayou YT, Bazargan-Hejazi S, Beardsley J, Bedi N, Beghi E, Belay HA, Bell B, Bell ML, Bello AK, Bennett DA, Bensenor IM, Berhane A, Bernabé E, Betsu BD, Beyene AS, Bhala N, Bhalla A, Biadgilign S, Bikbov B, Abdulhak AAB, Biroscak BJ, Biryukov S, Bjertness E,

541 Blore JD, Blosser CD, Bohensky MA, Borschmann R, Bose D, Bourne RRA, Brainin M, Brayne
542 CEG, Brazinova A, Breitborde NJK, Brenner H, Brewer JD, Brown A, Brown J, Brugha TS,
543 Buckle GC, Butt ZA, Calabria B, Campos-Nonato IR, Campuzano JC, Carapetis JR, Cárdenas R,
544 Carpenter DO, Carrero JJ, Castañeda-Orjuela CA, Rivas JC, Catalá-López F, Cavalleri F, Cercy
545 K, Cerda J, Chen W, Chew A, Chiang PP-C, Chibalabala M, Chibueze CE, Chimed-Ochir O,
546 Chisumpa VH, Choi J-YJ, Chowdhury R, Christensen H, Christopher DJ, Ciobanu LG, Cirillo M,
547 Cohen AJ, Colistro V, Colomar M, Colquhoun SM, Cooper C, Cooper LT, Cortinovis M, Cowie
548 BC, Crump JA, Damsere-Derry J, Danawi H, Dandona R, Daoud F, Darby SC, Dargan PI, das
549 Neves J, Davey G, Davis AC, Davitoiu DV, de Castro EF, de Jager P, Leo DD, Degenhardt L,
550 Dellavalle RP, Deribe K, Deribew A, Dharmaratne SD, Dhillon PK, Diaz-Torné C, Ding EL, dos
551 Santos KPB, Dossou E, Driscoll TR, Duan L, Dubey M, Duncan BB, Ellenbogen RG, Ellingsen
552 CL, Elyazar I, Endries AY, Ermakov SP, Eshrati B, Esteghamati A, Estep K, Faghmous IDA,
553 Fahimi S, Faraon EJA, Farid TA, Farinha CS e S, Faro A, Farvid MS, Farzadfar F, Feigin VL,
554 Fereshtehnejad S-M, Fernandes JG, Fernandes JC, Fischer F, Fitchett JRA, Flaxman A, Foigt
555 N, Fowkes FGR, Franca EB, Franklin RC, Friedman J, Frostad J, Fürst T, Futran ND, Gall SL,
556 Gambashidze K, Gamkrelidze A, Ganguly P, Gankpé FG, Gebre T, Gebrehiwot TT,
557 Gebremedhin AT, Gebru AA, Geleijnse JM, Gessner BD, Ghoshal AG, Gibney KB, Gillum RF,
558 Gilmour S, Giref AZ, Giroud M, Gishu MD, Giussani G, Glaser E, Godwin WW, Gomez-Dantes
559 H, Gona P, Goodridge A, Gopalani SV, Gosselin RA, Gotay CC, Goto A, Gouda HN, Greaves F,
560 Gugnani HC, Gupta R, Gupta R, Gupta V, Gutiérrez RA, Hafezi-Nejad N, Haile D, Hailu AD,
561 Hailu GB, Halasa YA, Hamadeh RR, Hamidi S, Hancock J, Handal AJ, Hankey GJ, Hao Y, Harb
562 HL, Harikrishnan S, Haro JM, Havmoeller R, Heckbert SR, Heredia-Pi IB, Heydarpour P,

563 Hilderink HBM, Hoek HW, Hogg RS, Horino M, Horita N, Hosgood HD, Hotez PJ, Hoy DG,
564 Hsairi M, Htet AS, Htike MMT, Hu G, Huang C, Huang H, Huiart L, Hussein A, Huybrechts I,
565 Huynh G, Iburg KM, Innos K, Inoue M, Iyer VJ, Jacobs TA, Jacobsen KH, Jahanmehr N,
566 Jakovljevic MB, James P, Javanbakht M, Jayaraman SP, Jayatilleke AU, Jeemon P, Jensen PN,
567 Jha V, Jiang G, Jiang Y, Jibat T, Jimenez-Corona A, Jonas JB, Joshi TK, Kabir Z, Kamal R, Kan H,
568 Kant S, Karch A, Karema CK, Karimkhani C, Karletsos D, Karthikeyan G, Kasaeian A, Katibeh
569 M, Kaul A, Kawakami N, Kayibanda JF, Keiyoro PN, Kemmer L, Kemp AH, Kengne AP, Keren
570 A, Kereselidze M, Kesavachandran CN, Khader YS, Khalil IA, Khan AR, Khan EA, Khang Y-H,
571 Khera S, Khoja TAM, Kieling C, Kim D, Kim YJ, Kissela BM, Kissoon N, Knibbs LD, Knudsen AK,
572 Kokubo Y, Kolte D, Kopec JA, Kosen S, Koul PA, Koyanagi A, Krog NH, Defo BK, Bicer BK,
573 Kudom AA, Kuipers EJ, Kulkarni VS, Kumar GA, Kwan GF, Lal A, Lal DK, Lalloo R, Lallukka T,
574 Lam H, Lam JO, Langan SM, Lansingh VC, Larsson A, Laryea DO, Latif AA, Lawrynnowicz AEB,
575 Leigh J, Levi M, Li Y, Lindsay MP, Lipshultz SE, Liu PY, Liu S, Liu Y, Lo L-T, Logroscino G, Lotufo
576 PA, Lucas RM, Lunevicius R, Lyons RA, Ma S, Machado VMP, Mackay MT, MacLachlan JH,
577 Razek HMAE, Magdy M, Razek AE, Majdan M, Majeed A, Malekzadeh R, Manamo WAA,
578 Mandisarisa J, Mangalam S, Mapoma CC, Marcenes W, Margolis DJ, Martin GR, Martinez-
579 Raga J, Marzan MB, Masiye F, Mason-Jones AJ, Massano J, Matzopoulos R, Mayosi BM,
580 McGarvey ST, McGrath JJ, McKee M, McMahon BJ, Meaney PA, Mehari A, Mehndiratta
581 MM, Mejia-Rodriguez F, Mekonnen AB, Melaku YA, Memiah P, Memish ZA, Mendoza W,
582 Meretoja A, Meretoja TJ, Mhimbira FA, Micha R, Millear A, Miller TR, Mirarefin M,
583 Misganaw A, Mock CN, Mohammad KA, Mohammadi A, Mohammed S, Mohan V, Mola
584 GLD, Monasta L, Hernandez JCM, Montero P, Montico M, Montine TJ, Moradi-Lakeh M,

585 Morawska L, Morgan K, Mori R, Mozaffarian D, Mueller UO, Murthy GVS, Murthy S, Musa
586 KI, Nachega JB, Nagel G, Naidoo KS, Naik N, Naldi L, Nangia V, Nash D, Nejari C, Neupane S,
587 Newton CR, Newton JN, Ng M, Ngalesoni FN, de Dieu Ngirabega J, Nguyen QL, Nisar MI,
588 Pete PMN, Nomura M, Norheim OF, Norman PE, Norrving B, Nyakarahuka L, Ogbo FA,
589 Ohkubo T, Ojelabi FA, Olivares PR, Olusanya BO, Olusanya JO, Opio JN, Oren E, Ortiz A,
590 Osman M, Ota E, Ozdemir R, Pa M, Pain A, Pandian JD, Pant PR, Papachristou C, Park E-K,
591 Park J-H, Parry CD, Parsaeian M, Caicedo AJP, Patten SB, Patton GC, Paul VK, Pearce N,
592 Pedro JM, Stokic LP, Pereira DM, Perico N, Pesudovs K, Petzold M, Phillips MR, Piel FB, Pillay
593 JD, Plass D, Platts-Mills JA, Polinder S, Pope CA, Popova S, Poulton RG, Pourmalek F,
594 Prabhakaran D, Qorbani M, Quame-Amaglo J, Quistberg DA, Rafay A, Rahimi K, Rahimi-
595 Movaghar V, Rahman M, Rahman MHU, Rahman SU, Rai RK, Rajavi Z, Rajsic S, Raju M,
596 Rakovac I, Rana SM, Ranabhat CL, Rangaswamy T, Rao P, Rao SR, Refaat AH, Rehm J,
597 Reitsma MB, Remuzzi G, Resnikoff S, Ribeiro AL, Ricci S, Blancas MJR, Roberts B, Roca A,
598 Rojas-Rueda D, Ronfani L, Roshandel G, Rothenbacher D, Roy A, Roy NK, Ruhago GM, Sagar
599 R, Saha S, Sahathevan R, Saleh MM, Sanabria JR, Sanchez-Niño MD, Sanchez-Riera L, Santos
600 IS, Sarmiento-Suarez R, Sartorius B, Satpathy M, Savic M, Sawhney M, Schaub MP, Schmidt
601 MI, Schneider IJC, Schöttker B, Schutte AE, Schwebel DC, Seedat S, Sepanlou SG, Servan-
602 Mori EE, Shackelford KA, Shaddick G, Shaheen A, Shahraz S, Shaikh MA, Shakh-Nazarova M,
603 Sharma R, She J, Sheikhbahaei S, Shen J, Shen Z, Shepard DS, Sheth KN, Shetty BP, Shi P,
604 Shibuya K, Shin M-J, Shiri R, Shiue I, Shrimme MG, Sigfusdottir ID, Silberberg DH, Silva DAS,
605 Silveira DGA, Silverberg JI, Simard EP, Singh A, Singh GM, Singh JA, Singh OP, Singh PK, Singh
606 V, Soneji S, Søreide K, Soriano JB, Sposato LA, Sreeramareddy CT, Stathopoulou V, Stein DJ,

Stein MB, Stranges S, Stroumpoulis K, Sunguya BF, Sur P, Swaminathan S, Sykes BL, Szoeki
CEI, Tabarés-Seisdedos R, Tabb KM, Takahashi K, Takala JS, Talongwa RT, Tandon N,
Tavakkoli M, Taye B, Taylor HR, Ao BJT, Tedla BA, Tefera WM, Have MT, Terkawi AS, Tesfay
FH, Tessema GA, Thomson AJ, Thorne-Lyman AL, Thrift AG, Thurston GD, Tillmann T,
Tirschwell DL, Tonelli M, Topor-Madry R, Topouzis F, Towbin JA, Traebert J, Tran BX,
Truelsen T, Trujillo U, Tura AK, Tuzcu EM, Uchendu US, Ukwaja KN, Undurraga EA, Uthman
OA, Dingenen RV, van Donkelaar A, Vasankari T, Vasconcelos AMN, Venketasubramanian N,
Vidavalur R, Vijayakumar L, Villalpando S, Violante FS, Vlassov VV, Wagner JA, Wagner GR,
Wallin MT, Wang L, Watkins DA, Weichenthal S, Weiderpass E, Weintraub RG, Werdecker A,
Westerman R, White RA, Wijeratne T, Wilkinson JD, Williams HC, Wiysonge CS,
Woldeyohannes SM, Wolfe CDA, Won S, Wong JQ, Woolf AD, Xavier D, Xiao Q, Xu G, Yakob
B, Yalew AZ, Yan LL, Yano Y, Yaseri M, Ye P, Yebayo HG, Yip P, Yirsaw BD, Yonemoto N, Yonga
G, Younis MZ, Yu S, Zaidi Z, Zaki MES, Zannad F, Zavala DE, Zeeb H, Zeleke BM, Zhang H,
Zodpey S, Zonies D, Zuhlke LJ, Vos T, Lopez AD, Murray CJL. 2016. Global, regional, and
national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of
death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The
Lancet 388:1459–1544.

2. Marie C, Petri WA. 2013. Amoebic dysentery. *BMJ Clin Evid* 2013:0918.

3. Alvarado-Esquivel C, Hernandez-Tinoco J, Sanchez-Anguiano LF. 2015. Seroepidemiology of
Entamoeba histolytica Infection in General Population in Rural Durango, Mexico. *J Clin Med*
Res 7:435–439.

4. Gilchrist CA, Petri SE, Schneider BN, Reichman DJ, Jiang N, Begum S, Watanabe K, Jansen CS, Elliott KP, Burgess SL, Ma JZ, Alam M, Kabir M, Haque R, Petri WA. 2016. Role of the Gut Microbiota of Children in Diarrhea Due to the Protozoan Parasite *Entamoeba histolytica*. *J Infect Dis* 213:1579–1585.
5. Haque R, Huston CD, Hughes M, Houpt E, Petri WA. 2003. Amebiasis. *New England Journal of Medicine* 348:1565–1573.
6. Petri WA, Haque R, Mann BJ. 2002. The Bittersweet Interface of Parasite and Host: Lectin-Carbohydrate Interactions During Human Invasion by the Parasite *Entamoeba histolytica*. *Annu Rev Microbiol* 56:39–64.
7. Reed SL, Curd JG, Gigli I, Gillin FD, Braude AI. 1986. Activation of complement by pathogenic and nonpathogenic *Entamoeba histolytica*. *J Immunol* 136:2265–2270.
8. Costa CA, Nunes AC, Ferreira AJ, Gomes MA, Caliri MV. 2010. *Entamoeba histolytica* and *E. dispar* trophozoites in the liver of hamsters: in vivo binding of antibodies and complement. *Parasites & Vectors* 3:23.
9. Reed SL, Ember JA, Herdman DS, DiScipio RG, Hugli TE, Gigli I. 1995. The extracellular neutral cysteine proteinase of *Entamoeba histolytica* degrades anaphylatoxins C3a and C5a. *J Immunol* 155:266–274.
10. Reed SL, Gigli I. 1990. Lysis of complement-sensitive *Entamoeba histolytica* by activated terminal complement components. Initiation of complement activation by an extracellular neutral cysteine proteinase. *J Clin Invest* 86:1815–1822.

- 648 11. Reed SL, Keene WE, McKerrow JH, Gigli I. 1989. Cleavage of C3 by a neutral cysteine
649 proteinase of *Entamoeba histolytica*. *J Immunol* 143:189–195.
- 650 12. Braga LL, Ninomiya H, McCoy JJ, Eacker S, Wiedmer T, Pham C, Wood S, Sims PJ, Petri WA.
651 1992. Inhibition of the complement membrane attack complex by the galactose-specific
652 adhesion of *Entamoeba histolytica*. *J Clin Invest* 90:1131–1137.
- 653 13. Miller HW, Suleiman RL, Ralston KS. 2019. Trogocytosis by *Entamoeba histolytica* Mediates
654 Acquisition and Display of Human Cell Membrane Proteins and Evasion of Lysis by Human
655 Serum. *mBio* 10:e00068-19.
- 656 14. Bettadapur A, Miller HW, Ralston KS. 2020. Biting Off What Can Be Chewed: Trogocytosis in
657 Health, Infection, and Disease. *Infect Immun* 88:e00930-19.
- 658 15. Ralston KS, Solga MD, Mackey-Lawrence NM, Somlata null, Bhattacharya A, Petri WA.
659 2014. Trogocytosis by *Entamoeba histolytica* contributes to cell killing and tissue invasion.
660 *Nature* 508:526–530.
- 661 16. González-Ruiz A, Haque R, Aguirre A, Castañón G, Hall A, Guhl F, Ruiz-Palacios G, Miles MA,
662 Warhurst DC. 1994. Value of microscopy in the diagnosis of dysentery associated with
663 invasive *Entamoeba histolytica*. *J Clin Pathol* 47:236–239.
- 664 17. Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H. 1989.
665 CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the
666 complement membrane attack complex on homologous cells. *Journal of Experimental*
667 *Medicine* 170:637–654.

18. Štefanová I, Hilgert I, Křištofová H, Brown R, Low MG, Hořejši V. 1989. Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol. *Molecular Immunology* 26:153–161.
19. Cinek T, Horejší V. 1992. The nature of large noncovalent complexes containing glycosyl-phosphatidylinositol-anchored membrane glycoproteins and protein tyrosine kinases. *The Journal of Immunology* 149:2262–2270.
20. Rollins SA, Sims PJ. 1990. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. *J Immunol* 144:3478–3483.
21. Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ. 1990. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. *Immunology* 71:1–9.
22. Zhao J, Rollins SA, Maher SE, Bothwell AL, Sims PJ. 1991. Amplified gene expression in CD59-transfected Chinese hamster ovary cells confers protection against the membrane attack complex of human complement. *J Biol Chem* 266:13418–13422.
23. Ventura-Juárez J, Campos-Rodríguez R, Jarillo-Luna RA, Muñoz-Fernández L, Escario-G-Trevijano JA, Pérez-Serrano J, Quintanar JL, Salinas E, Villalobos-Gómez FR. 2009. Trophozoites of *Entamoeba histolytica* express a CD59-like molecule in human colon. *Parasitol Res* 104:821–826.

24. Wang G, Liszewski MK, Chan AC, Atkinson JP. 2000. Membrane Cofactor Protein (MCP; CD46): Isoform-Specific Tyrosine Phosphorylation. *The Journal of Immunology* 164:1839–1846.
25. Riley-Vargas RC, Gill DB, Kemper C, Liszewski MK, Atkinson JP. 2004. CD46: expanding beyond complement regulation. *Trends in Immunology* 25:496–503.
26. Liszewski MK, Atkinson JP. 2015. Complement regulator CD46: genetic variants and disease associations. *Human Genomics* 9:7.
27. Seya T, Turner JR, Atkinson JP. 1986. Purification and characterization of a membrane protein (gp45-70) that is a cofactor for cleavage of C3b and C4b. *J Exp Med* 163:837–855.
28. Goslings WR, Blom DJ, de Waard-Siebinga I, van Beelen E, Claas FH, Jager MJ, Gorter A. 1996. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. *Invest Ophthalmol Vis Sci* 37:1884–1891.
29. Varsano S, Rashkovsky L, Shapiro H, Ophir D, Mark-Bentankur T. 1998. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. *Clin Exp Immunol* 113:173–182.
30. Nicholson-Weller A, Burge J, Fearon DT, Weller PF, Austen KF. 1982. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. *The Journal of Immunology* 129:184–189.

- 706 31. Medof ME, Kinoshita T, Nussenzweig V. 1984. Inhibition of complement activation on the
707 surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
708 J Exp Med 160:1558–1578.
- 709 32. Fishelson Z, Donin N, Zell S, Schultz S, Kirschfink M. 2003. Obstacles to cancer
710 immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in
711 tumors. Molecular Immunology 40:109–123.
- 712 33. Gelderman KA, Blok VT, Fleuren GJ, Gorter A. 2002. The Inhibitory Effect of CD46, CD55, and
713 CD59 on Complement Activation After Immunotherapeutic Treatment of Cervical
714 Carcinoma Cells with Monoclonal Antibodies or Bispecific Monoclonal Antibodies. Lab
715 Invest 82:483–493.
- 716 34. Jurianz K, Maslak S, Garcia-Schüler H, Fishelson Z, Kirschfink M. 1999. Neutralization of
717 complement regulatory proteins augments lysis of breast carcinoma cells targeted with
718 rhumAb anti-HER2. Immunopharmacology 42:209–218.
- 719 35. Suleiman RL, Ralston KS. Growth and genetic manipulation of *Entamoeba histolytica*.
720 Current Protocols in Microbiology.
- 721 36. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA,
722 Zhang F. 2013. Multiplex genome engineering using CRISPR/Cas systems. Science 339:819–
723 823.

37. Thielen AJF, van Baarsen IM, Jongsma ML, Zeerleder S, Spaapen RM, Wouters D. 2018. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research. *Journal of Immunological Methods* 456:15–22.
38. Saito-Nakano Y, Yasuda T, Nakada-Tsukui K, Leippe M, Nozaki T. 2004. Rab5-associated Vacuoles Play a Unique Role in Phagocytosis of the Enteric Protozoan Parasite *Entamoeba histolytica**. *Journal of Biological Chemistry* 279:49497–49507.
39. Saffer LD, Petri WA. 1991. Role of the galactose lectin of *Entamoeba histolytica* in adherence-dependent killing of mammalian cells. *Infect Immun* 59:4681–4683.
40. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9:676–682.

FIGURE LEGENDS

Figure 1: Ingestion of latex beads does not protect amoebae from complement lysis

Amoebae were incubated with 3×10^6 or 1.5×10^7 fluorescent latex beads for 1 hour or were incubated without latex beads, and then exposed to human serum. Amoebic viability was determined with Zombie Violet viability dye. Imaging flow cytometry was used to quantify bead ingestion and amoebic viability. **(A)** The percentage of amoebae that had ingested any number of latex beads. **(B)** Mean number of ingested beads among amoebae that had ingested beads. **(C)** Normalized amoeba death following exposure to human serum. Values are normalized to the amoebae that were incubated without latex beads. **(D)** Quantification of the number of ingested beads per amoeba; shown are the data plots from one replicate per sample type. Amoebae that did not perform bead ingestion fall into the “Bead –” gate, while amoebae that ingested beads fall into the “Bead +” gate. **(G)** Representative images of amoebae that were incubated without beads, or in the presence of 3×10^6 or 1.5×10^7 beads. Ingested beads are shown in yellow. Data are from four replicates across two independent experiments.

Figure 2: Amoebic protection from complement following trophocytosis is dose-dependent.

Amoebae were labeled with CMFDA cytoplasm dye and incubated in the absence of human cells, or with increasing concentrations of human Jurkat cells or primary human red blood cells. Human cells were labeled with DiD membrane dye. Following exposure to human serum, amoeba death was assessed with Zombie Violet viability dye and ingested human cell material was determined by quantifying mean fluorescence intensity (MFI) of DiD present on amoebae. **(A)** Normalized MFI of DiD on amoebae incubated in the absence of Jurkat cells or with increasing concentrations of Jurkat cells. **(B)** Normalized death of amoebae from conditions in

panel A. **(C)** Death of amoebae from conditions in panel A, expressed as percent protection. Percent protection was calculated by subtracting the total death of amoebae incubated with human cells from the total death of amoebae incubated in the absence of Jurkat cells. **(D)** Normalized MFI of DiD on amoebae incubated in the absence of red blood cells or with increasing concentrations of red blood cells. **(E)** Normalized death of amoebae from conditions in panel D. **(F)** Death of amoebae from conditions in panel D, expressed as percent protection. **(G)** Representative images of amoebae incubated with increasing concentrations of Jurkat cells. Amoebae are shown in green and ingested human cell material is shown in red. Data were analyzed by imaging flow cytometry and are from 6 replicates across 3 independent experiments. **(H)** Representative images of amoebae incubated with red blood cells. Data were analyzed by imaging flow cytometry and are from 6 replicates across 3 independent experiments.

Figure 3: Amoebic trogocytosis of human cells inhibits deposition of complement C3b.

Amoebae were incubated in the absence of Jurkat T cells or in the presence of Jurkat cells, and subsequently exposed to human serum. Viability was assessed with Zombie Violet dye. The presence of C3b was detected using a mouse monoclonal antibody to C3b and iC3b. **(A)** Death of amoebae that were incubated in the absence of Jurkat cells or in the presence of Jurkat cells. **(B)** Mean fluorescence intensity of deposited C3b on amoebae. **(C)** Deposited C3b on dead or live amoebae. **(D)** Deposited C3b on dead or live amoebae that had been incubated in the absence of Jurkat cells (open circles) or in the presence of Jurkat cells (filled circles). **(E)** Representative images of C3b deposition (red) on live or dead amoebae. Data were analyzed by imaging flow cytometry and are from 6 replicates across 3 independent experiments.

Figure 4: Amoebae acquire and display the complement regulatory protein CD59 from human cells.

Amoebae were allowed to perform trogocytosis on human Jurkat T cells for 5 minutes or 1 hour, or were incubated in the absence of Jurkat cells. Human CD59 (red) was detected on the amoebae surface by monoclonal antibody staining. Amoebae were labeled with CMFDA (green) and human cell nuclei were labeled with Hoechst (blue). **(A)** Representative images from amoebae incubated in the absence of Jurkat cells or amoebae that performed trogocytosis on human Jurkat T cells for 5 minutes or 1 hour. Arrows indicate patches of displayed CD59 on the amoeba surface. **(B)** 3D rendering of Z stack images taken from amoebae that were incubated with human Jurkat T cells for 1 hour. **(C)** Zoomed in image of amoebae that were incubated with human Jurkat T cells for 1 hour. Data were analyzed by confocal microscopy. 136 Images were collected from 1 independent experiment.

Figure 5: The amount of displayed CD59 increases with increased trogocytosis of human cells.

Acquired CD59 molecules were quantified on amoebae that were allowed to perform trogocytosis on human Jurkat T cells for 5 minutes or 1 hour, or were incubated in the absence of Jurkat cells. **(A)** Masking strategy for analysis of displayed CD59 on the amoeba surface. A mask was created in order to allow for the detection of CD59 that overlapped with amoebae, while excluding CD59 on intact human cells attached to amoebae. The mask is displayed in turquoise, as an overlay on the individual images. Amoebae were labeled with CMFDA (green), human cell nuclei were labeled with Hoechst (blue), and CD59 was detected with a monoclonal antibody (red). Extracellular human cell nuclei fluorescence was removed from the masked analysis area. The excluded area around human cell nuclei was then dilated by 4 pixels to

include the entire diameter of the intact extra-cellular human cells and associated CD59. CD59 was analyzed in the remaining masked analysis area of each image to allow for analysis of displayed patches of acquired CD59 on amoebae. **(B)** The normalized mean fluorescence intensity of CD59 on amoebae after 5 minutes or 1 hour of trogocytosis or amoebae that were incubated in the absence of Jurkat cells. To normalize the data, samples were normalized to the 1 hour of trogocytosis condition. **(C)** Representative images of amoebae that had performed trogocytosis on human Jurkat T cells for 5 minutes or 1 hour. Arrows indicate displayed CD59. Data were analyzed by imaging flow cytometry and are from 5 replicates across 3 independent experiments. The no primary control condition was performed in 2 of 3 independent experiments and data are from 3 replicates.

Figure 6: Removal of CD59 and CD46 is not sufficient to sensitize amoebae to complement lysis.

(A-D) Human Jurkat T cells deficient in CD59 or CD46 were constructed using CRISPR/Cas9. Immunofluorescence and imaging flow cytometry were used to quantify CD59 or CD46. **(A)** Representative images of CD59 antibody staining (red) in vector control human cells or CD59 mutants. **(B)** Intensity of CD59 antibody staining in vector control human cells (gray) or CD59 mutants (black). 99.5% of CD59 mutants were in the CD59-negative gate ("CD59⁻"), while 0.75% of vector control cells were in this gate. **(C)** Representative images of CD46 antibody staining (red) in vector control human cells or CD46 mutants. **(D)** Intensity of CD46 antibody staining in vector control human cells (gray) or CD46 mutants (black). 99.5% of CD46 mutants were in the CD46-negative gate ("CD46⁻"), while 0.27% of vector control cells were in this gate. **(E-F)** Amoebae were labeled with CMFDA cytoplasm dye and incubated in the absence of Jurkat cells

or with Jurkat cells. Human cell lines were either vector control cells, CD59 KO mutants, or CD46 KO mutants. Human cells were labeled with DiD membrane dye. Following exposure to human serum, amoeba death was assessed with Zombie Violet viability dye and ingested human cell material was determined by quantifying mean fluorescence intensity (MFI) of DiD present on amoebae. **(E)** Normalized death of amoebae. **(F)** Normalized mean fluorescence intensity of DiD on amoebae. Data were analyzed by imaging flow cytometry and are from 6 replicates across 3 independent experiments.

Figure 7: Amoebae transfected with expression plasmids display human CD46 or CD55.

Amoebae were transfected with expression constructs for human CD46 or human CD55, or the expression plasmid backbone as a negative control. **(A)** RT-PCR analysis with primers specific for human CD46, human CD55, or amoebic GAPDH. Samples were incubated with or without reverse transcriptase (RT +/-), to control for DNA contamination. **(B-J)** Amoebae were labeled with a cytoplasmic dye (CMFDA) and immunofluorescence was performed without permeabilization. **(B)** Mean fluorescence intensity of human CD46 antibody staining. Amoebae were stably transfected with a plasmid for expression of human CD46 (red) or vector backbone (beige), and were stained using a CD46 primary antibody and a far red secondary antibody. Amoebae expressing human CD46 were also incubated without primary antibody (grey), or without any antibodies (black). **(C)** Mean fluorescence intensity of human CD55 antibody staining. Amoebae were stably transfected with a plasmid for expression of human CD55 (blue) or vector backbone (beige), and were stained using a CD46 primary antibody and a far red secondary antibody. Amoebae expressing human CD55 were also incubated without primary antibody (grey), or without any antibodies (black). **(D)** Mean fluorescence intensity of amoebic

Gal/GalNAc lectin antibody staining. Amoebae were stably transfected with a plasmid for expression of human CD46 (red), or human CD55 (blue), or vector backbone (beige), and were stained using a Gal/GalNAc lectin primary antibody and a far red secondary antibody. Amoebae were also incubated without primary antibody, or without any antibodies. **(E-G)** Histograms corresponding to the mean fluorescence intensity data shown in panels B-D. Panel G shows antibody staining of vector control amoebae, stained with both antibodies (beige), without primary antibody (grey), or without any antibodies (black). **(H-J)** Representative images corresponding to the analysis shown in panels B-G. Data shown in panel A are representative of two replicates. Data shown in panels B-J were analyzed by imaging flow cytometry are from 3-4 replicates across 2 independent experiments; the data from one independent experiment are shown.

Figure 8: Display of human CD46 or CD55 is sufficient to protect amoebae from complement lysis.

Amoebae were stably transfected with CD46 or CD55 expression constructs, or vector backbone. Following exposure to either media or human serum, amoeba viability was assessed using Zombie Violet viability dye and imaging flow cytometry. Amoebic death was normalized to vector control amoebae that were incubated with human serum. These data are from 8 replicates across 4 independent experiments.

865 TABLES

866 **Table 1: Primers used in these studies.**

Purpose	Primer Name	F/R	Sequence
Cloning of guide RNAs into the pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid backbone	CD59 gRNA (BbsI overhang)	Forward	CACCGCAAGGAGGGTCTGTCCTGTT
	CD59 gRNA (BbsI overhang)	Reverse	AAACAACAGGACAGACCCTCCTTGC
	CD46 gRNA (BbsI overhang)	Forward	CACCGAAAGGGACACTCGCGGCGGC
	CD46 gRNA (BbsI overhang)	Reverse	AAACGCCGCCGCGAGTGTCCCTTTC
Sanger sequencing of CRISPR gRNA plasmids	GENEWIZ Universal Primer "U6"	Forward	GACTATCATATGCTTACCGT
BLAST-identified primer sets for specific PCR amplification of CD59 and CD46	CD59 PCR amplification	Forward	TTGACTCACTGACCCTGATGG
	CD59 PCR amplification	Reverse	TATCCATTGGTGTCCCCAAGC
	CD46 PCR amplification	Forward	ACAAATATGACGGCGAGCCA
	CD46 PCR amplification	Reverse	GGCTCAATCCCGAAAACACG
Sanger Sequencing of PCR product from CRISPR knockout clones	CD59 sequencing	Forward	GGGGCTTATAGGGACTGAGC
	CD46 sequencing	Forward	ACCTCTCGAAGGCCAAGG
Gibson cloning of CD46 and CD55 coding sequences into a pEhEx plasmid backbone	CD55 coding sequence (homology to pEhEx)	Forward	AAACACATTAACAGATCTTCATGACCGTCGCGGCGCCGAG
	CD55 coding sequence (homology to pEhEx)	Reverse	GAAGAGTTCAACTCGAGTGGCTAAGTCAGCAAGCCCATGG
	CD46 coding sequence (homology to pEhEx)	Forward	AAACACATTAACAGATCTTCATGGAGCCTCCCGGCCGCCG
	CD46 coding sequence (homology to pEhEx)	Reverse	GAAGAGTTCAACTCGAGTGGTCAGCCTCTCTGCTCTGCTG
	pEhEx (homology to CD46 coding sequence)	Forward	CAGCAGAGCAGAGAGGCTGACCACTCGAGTTGAACTCTTC
	pEhEx (homology to CD46 coding sequence)	Reverse	CGGCGGCCCGGGAGGCTCCATGAAGATCTGTTAATGTGTTT

Sequencing of CD59 and CD46 expression plasmids	pEhEx CS UTR Primer	Forward	TCAGTCTTACCACGTCATAAAGT
	pEhEx CS UTR Primer	Reverse	TGCAAGAAGATGTTACAAAGCA
RT-PCR of amoebae mutants	CD46 RT-PCR	Forward	TCCCTGCAAATGGGACTTAC
	CD46 RT-PCR	Reverse	GGGGGATCCCAAGTACTGTT
	CD55 RT-PCR	Forward	ATGAGTGCCGTCCAGGTTAC
	CD55 RT-PCR	Reverse	CTGAACTGTTGGTGGGACCT

867

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL FIGURE LEGENDS

Figure S1: Gating strategy used for analysis of bead ingestion experiments

Amoebae were gated on by brightfield area and aspect ratio during acquisition. Next, using Gradient RMS Bright Field, focused cells were gated on from total collected events. Because amoebae remained unstained in these experiments, single amoebae were then gated on using brightfield area and aspect ratio. From the single amoebae population, amoebae viability and bead ingestion were measured. Dead amoebae were gated on using fluorescence intensity of Zombie Violet dye and side scatter. Bead ingestion was quantified using the “spot count” feature in Amnis IDEAS software and quantified spots of red bead fluorescence.

Figure S2: Gating strategy used for analysis of experiments with increasing numbers of human cells, and for immunofluorescence analysis of amoebae exogenously expressing CD46 or CD55.

(A) Gating strategy for experiments with increasing numbers of Jurkat cells, and for immunofluorescence analysis of amoebae exogenously expressing CD46 or CD55. Focused cells were gated on from total collected events, using Gradient RMS Bright Field. Single amoebae were gated using area and aspect ratio of CMFDA cytoplasm dye fluorescence. Dead amoebae were gated on using fluorescence intensity of Zombie Violet dye and side scatter. **(B)** Gating strategy for experiments with increasing numbers of red blood cells. Only amoeba events were collected for analysis and were gated on using bright field area and aspect ratio during data acquisition. Focused cells were gated on from total collected events, using Gradient RMS Bright Field. Single amoebae were gated using area and aspect ratio of CMFDA cytoplasm dye

fluorescence. Dead amoebae were gated on using fluorescence intensity of Zombie Violet dye and side scatter.

Figure S3: Gating strategy used for analysis of C3b deposition experiments.

(A) Focused cells were gated on from total collected events, using Gradient RMS Bright Field. Single amoebae were gated using area and aspect ratio of CMFDA cytoplasm dye fluorescence. Dead amoebae were gated on using fluorescence intensity of Zombie Violet dye and side scatter. **(B)** Representative histograms of C3b fluorescence intensity of all single amoeba, live amoeba, or dead amoeba populations.

Figure S4: Biotinylated human cell membrane proteins are detected on the surface of amoebae prior to fixation.

The surface of human Jurkat cells was biotinylated prior to incubation with amoebae. Following incubation, samples were placed on ice to halt membrane turnover and fluorescently-conjugated streptavidin was used to detect biotinylated proteins on the surface on both human cells and amoebae (magenta) prior to fixation. DNA was labeled with DAPI nucleic acid stain following fixation. Arrows indicate transferred patches of human proteins on the surface of amoebae. **(A)** Amoebae and biotinylated human cells were incubated together for 2 minutes. **(B)** A closeup image of an amoebae from the panel shown in A with transferred human proteins on its surface. **(C)** Amoebae and human cells were incubated together for 5 minutes. Amoebic autofluorescence is shown in green. **(D)** 3-D reconstruction of Z stacks taken from the data in C. **(E-F)** Human cells and amoebae were incubated together for 5 minutes. Amoebae cytoplasm was labeled with CMFDA dye (green), and the nuclei of cells were left unstained. Data were

analyzed by confocal microscopy. Images in A-F are representative of data collected from 4 independent experiments with incubation times of 2-5 minutes.

Figure S5: Gating strategy used for analysis of CD59 displayed on amoebae after 5 minutes and 1 hour of trogocytosis.

A masking strategy was developed to quantify only fluorescence of CD59 present on the amoebae, and not on extracellular human cells. **(A)** Focused cells were gated on from total collected events, using Gradient RMS Bright Field. Single amoebae were gated using area and aspect ratio of CMFDA cytoplasm dye fluorescence. Next, fluorescence intensity of CD59 inside of the masked area was measured. **(B)** Representative images of bright field, amoeba cytoplasm, human cell nuclei, and CD59 fluorescence with the masked area (turquoise) applied as an overlay.

Figure S6: Amoebae acquire and display the complement regulatory protein CD46 from human cells.

Amoebae were incubated in the absence of Jurkat T cells, or were allowed to perform trogocytosis on human Jurkat cells for 5 minutes. Human cell nuclei were pre-labeled with Hoechst (blue), and amoebae were pre-labeled with CMFDA (green). Human CD46 (red) was detected on the amoebae surface by monoclonal antibody staining. **(A)** Representative images from amoebae that were incubated in the absence of Jurkat cells. **(B)** Representative images of amoebae that performed trogocytosis on human Jurkat cells for 5 minutes. Arrows indicate patches of displayed CD46 on the amoeba surface. Data were analyzed by imaging flow cytometry and are from 2 replicates and 1 independent experiment.

Figure S7: Removal of GPI-anchored surface proteins using phosphatidylinositol-specific phospholipase C.

Amoebae were labeled with CMFDA cytoplasm dye and incubated in the absence of Jurkat cells or with Jurkat cells. Human cells were labeled with DiD membrane dye. Samples were then treated with phosphatidylinositol-specific phospholipase C (PI-PLC) to remove GPI-anchored proteins, or heat-inactivated phosphatidylinositol-specific phospholipase C (HI-PI-PLC) as a control. Following exposure to human serum, amoeba death was assessed with Zombie Violet viability dye and ingested human cell material was determined by quantifying mean fluorescence intensity (MFI) of DiD present on amoebae. **(A)** Normalized death of amoebae. **(B)** Normalized mean fluorescence intensity of DiD on amoebae. Data were analyzed by imaging flow cytometry and are from 8 replicates across 4 independent experiments. The untreated control condition was performed 3 of 4 independent experiments and data are from 6 replicates.

Figure S8: Gating strategy used for analysis of experiments with CRISPR knockout mutants, PI-PLC treatment experiments, amoebae exogenously expressing CD46 or CD55.

Only cell events were collected for analysis (to minimize collection of debris) and were gated on using bright field area and aspect ratio during data acquisition. Focused cells were gated on from total collected events, using Gradient RMS Bright Field. Single amoebae were gated using intensity of and aspect ratio of CMFDA cytoplasm dye fluorescence. **(A)** In CRISPR knockout mutant and PI-PLC treatment experiments, amoebae were gated on a second time using CMFDA fluorescence intensity and side scatter to eliminate remaining clumps of human cells from the analysis. **(B)** In experiments with amoebae exogenously expressing CD46 or CD55, the

954 second amoebae gate was not used. Finally, dead amoebae were gated on using fluorescence
955 intensity of Zombie Violet dye and side scatter.

956 **Figure S9: Sequencing analysis of Jurkat CRISPR/Cas9 mutants.**

957 Chromatograms from Sanger sequencing analysis of Jurkat T cell CRISPR/Cas9 mutants.

958 Chromatograms from CD59 mutants **(A)** and CD46 mutants **(B)** show that the gene sequence of
959 the mutants is different from the vector control cells downstream of the gRNA/PAM sites.

Fig. 2

bioRxiv preprint doi: <https://doi.org/10.1101/2021.08.04.455151>; this version posted October 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 3

bioRxiv preprint doi: <https://doi.org/10.1101/2021.08.04.455151>; this version posted October 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Fig. 8